Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause...
Transcript of Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause...
![Page 1: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/1.jpg)
Treatment of Perimenopausal Women with Breast cancer
Alison L Jones
Royal Free and UCLH
November 2014
![Page 2: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/2.jpg)
Oestradiol levels in a female lifetime
1000pmol
150pmol
12 years 36 years 51 years
![Page 3: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/3.jpg)
Definition of menopause1
Menopause
Bilateral prior oophorectomy
Age >60 years Age <60 years
Amenorrhoea for
>12 months
Post-menopausal
FSH and oestradiol
concentrations
• Cannot assign menopausal status to women on
LHRH analogue therapy
• Amenorrhoea ≠ menopause on chemotherapy
1. Breast cancer. NCCN practice guidelines in oncology v.3; 2012.
![Page 4: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/4.jpg)
Many women fall into the perimenopausal range…
…and may become postmenopausal during their treatment Cancer Research UK http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/uk-breast-cancer-incidence-statistics Last accessed 10 Jan 2013.
Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population, Females, UK, 2008–2010
![Page 5: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/5.jpg)
Chemotherapy - Induced Amenorrhea Rates
Agents “Younger”
Women (≤40 y)
“Older”
Women (>40 y)
Alkylating 18% to 61% 61% to 97%
Anthracyclines ~ 32% ~ 88%
Taxanes (+Anthac.) ~ 61% ~ 84%
Walshe JM, et al. J Clin Oncol. 2006;24(36):5769-5779
![Page 6: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/6.jpg)
Goodwin PJ, et al. J Clin Oncol. 1999;17(8):2365-2370.
Mathematical Model of Risk of Menopause:
First Year After Diagnosis
0.2
0.4
0.6
0.8
1.0
0.0
25 30 35 40 45 50 55
None
Horm Only
Chem Only
Both
Age at Diagnosis, years
Esti
mate
d P
rob
ab
ilit
y
Our patient
![Page 7: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/7.jpg)
NICE guidelines for endocrine therapy
in pre/peri-menopausal ABC • Offer tamoxifen and ovarian suppression as first-line treatment to
premenopausal and perimenopausal women with ER-positive advanced breast cancer not previously treated with tamoxifen
• Offer ovarian suppression to premenopausal and perimenopausal women who have previously been treated with tamoxifen and then experience disease progression
NICE clinical guideline 81, 2009.
![Page 8: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/8.jpg)
Use of AIs in Perimenopause: Royal Marsden Experience
45 women
Median age 47 (39-52) years with CT induced amenorrhea
Treated with AIs (33 biochemically confirmed ovarian suppression)
– Recovery of ovarian function: 12 (27%)
– Pregnancies 1
– Median duration of amenorrhea: 12 (4-59) months
– Median time on AI: 6 (3-18) months
Smith IE, et al. J Clin Oncol. 2006;24(16): 2444-2447.
![Page 9: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/9.jpg)
Biochemical Monitoring of Ovarian Function in Perimenopause
• Single measurement of FSH, (LH), E2, beta inhibin reflects function only at that time point, but is not predictive
• Tests used for E2 measurements are highly unreliable in perimenopause, as they do not extract or purify E2 from plasma
• Measurement in patients receiving a steroidal AI cross-react even with most specialized immunoassays
Smith IE, et al. J Clin Oncol. 2006;24(16):2444-2447.
FSH, follicle-stimulating hormone; LH, luteinizing hormone
![Page 10: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/10.jpg)
Mrs A F (aged 49)
• 2010 Carcinoma right breast
– T2 N1 (2/9) M0
– 2.5 cm Grade 2 IDC with clear margins
• ER + Quick score 7/8
• PR + Quick score 4/8
• HER 2 Negative (IHC 0)
• No co-morbidities
• Mastectomy and axillary node clearance
![Page 11: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/11.jpg)
Mortality estimations with Adjuvantonline
![Page 12: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/12.jpg)
Addition of Chemotherapy to Endocrine in ER+ EBC EBCTCG 2005
![Page 13: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/13.jpg)
Mrs AF; Adjuvant treatment
• She receives 3 cycles of FEC (100)
followed by 3 cycles of docetaxel which
she tolerates well
![Page 14: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/14.jpg)
Q2: Initial Endocrine therapy option?
1. Decision based on FSH/E1 levels
2. Tamoxifen started
3. An Aromatase Inhibitor started
4. A combination of LHRH-Ag and AI
5. A combination of LHRH-AG and Tamoxifen
44 years; Last menses < 9 months; pT2,N1, M0
IDC, Grade III, ER/PgR [+], HER2 negative
![Page 15: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/15.jpg)
Tamoxifen Efficacy Does Not Differ
Significantly According to Patient Age
Annual Risk Ratio ± SE
Breast Cancer
Recurrence Rate
Breast Cancer
Death Rate
Risk Ratio SE Risk Ratio SE
For all age groups 0.59 0.03 0.66 0.04
Age, years
<40 0.56 0.10 0.61 0.12
40-49 0.71 0.07 0.76 0.09
50-59 0.66 0.05 0.76 0.07
60-69 0.55 0.05 0.65 0.06
≥70 0.49 0.12 0.63 0.15
Parton M, et al. J Clin Oncol. 2008;26(5):745-752 after Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2005:365(9472):1687-1717.
![Page 16: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/16.jpg)
Q2: Initial Endocrine therapy option?
1. Decision based on FSH/E1 levels
2. Tamoxifen started
3. An Aromatase Inhibitor started
4. A combination of LHRH-Ag and AI
5. A combination of LHRH-AG and Tamoxifen
![Page 17: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/17.jpg)
Patient case
30 months had gone
No relapse
Patient still on Tamoxifen
Good tolerance (Hot flashes first year)
Amenorrhea maintained (38 months)
![Page 18: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/18.jpg)
Q3: Is it time for switching endocrine therapy?
1. No discussion – switch to Exemestane
2. Exemestane but measuring FSH/E1 levels
3. Tamoxifen maintained for 5 years and then we
will see
![Page 19: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/19.jpg)
Coombes RC et al, Eur J Cancer Suppl. 2009;7(2): Abstract 5010.
Tamoxifen
R A N D O M I
ZE
Exemestane
(2-3 years)
Tamoxifen
(2-3 years)
Post-treatment follow-up
Diagnosis
Median follow-up from randomization = 91
months (June 2009)
Start of
study
Total 5 years
endocrine therapy
Total follow-up available from randomization at June 2009 analysis = 32296 women years
2-3 years
Intergroup Exemestane Study Design
![Page 20: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/20.jpg)
Long term results from the IES Study
Coombes RC et al, Eur J Cancer Suppl. 2009;7(2): Abstract 5010.
![Page 21: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/21.jpg)
If Use of AIs Is Considered in Perimenopause (Age <55 Years)
• Serial monthly measurement of FSH and E2
– For at least 6 months – For AI after tamoxifen situation even longer
• If E2 remains >10 pmol/L = AI is not fully effective
– Switch back to tamoxifen – Surgical ovarian ablation
• Instruct patients to contact clinician if menstrual bleed recurs or hot flushes
stop abruptly
• Adequate contraception should be practiced during monitoring period
• Anti Müllerian Hormone (AMH) is most reliable indicator of residual follicular function
Smith IE, et al. J Clin Oncol. 2006;24(16):2444-2447.
![Page 22: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/22.jpg)
Normal menopausal transition
• If postmenopausal
status cannot be
confirmed, treatment
with AIs alone is
contraindicated.
• Monitor E2 and
gonadotrophin levels
(ie, every 3-6 months)
to allow an AI when
postmenopausal
status is confirmed.
• The added value of
ovarian suppression
remains to be defined.
TREATMENT-NAÏVE:
NATURAL MENOPAUSAL
TRANSITION
TREATMENT-INDUCED AMENORRHOEA
Women of uncertain menopausal status who may be or may become eligible for an
adjuvant AI
CHEMOTHERAPY- INDUCED
WHILE ON TAMOXIFEN
AGE < 40: AI ALONE IS
CONTRAINDICATED
AGE > 40
Start with tamoxifen
Monitor E2 and FSH every
3-6 months
Consider an AI as soon as
menopausal status is confirmed
If E2 and FSH levels are post-menopausal by reliable & valid measure start AI
Monitor hormones at 3, 6 months and q6 during treatment
![Page 23: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/23.jpg)
• The effects of chemotherapy on ovarian function vary
• The likelihood of resumed ovarian function diminishes as a woman approaches the mean age of natural menopause (51 years)
• Women with CIA who are younger than 40 are more likely to resume ovarian function and should not receive an AI alone
Chemotherapy-induced amenorrhea (<40)
TREATMENT-NAÏVE: NATURAL MENOPAUSAL
TRANSITION
TREATMENT-INDUCED
AMENORRHOEA
Women of uncertain menopausal status who may be or may become eligible for an
adjuvant AI
CHEMOTHERAPY-
INDUCED
WHILE ON TAMOXIFEN
AGE < 40:
AI ALONE IS
CONTRAINDICATED
AGE > 40
Start with tamoxifen
Monitor E2 and FSH every 3-6 months
Consider an AI as soon as menopausal status is confirmed
If E2 and FSH levels are post-menopausal by reliable & valid measure start AI
Monitor hormones at 3, 6 months and q6 during treatment
![Page 24: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/24.jpg)
• In older women if E2
and FSH levels are
consistent with
postmenopausal status,
an AI can be started
• Undertake serial
monitoring at 3 and 6
months and then at
intervals of six months
during treatment
• If reliable testing is not
available, AIs should be
used with great caution
TREATMENT-NAÏVE: NATURAL MENOPAUSAL
TRANSITION
TREATMENT-INDUCED
AMENORRHOEA
Women of uncertain menopausal status who may be or may become eligible for an
adjuvant AI
CHEMOTHERAPY-
INDUCED
WHILE ON TAMOXIFEN
AGE < 40: AI ALONE IS
CONTRAINDICATED
AGE > 40
Start with tamoxifen
Monitor E2 and FSH every 3-6 months
Consider an AI as soon as menopausal status is confirmed
If E2 and FSH levels are post-menopausal by reliable & valid measure start AI
Monitor hormones at 3, 6 months and q6 during treatment
Chemotherapy-induced amenorrhea (>40)
![Page 25: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/25.jpg)
• If the patient is a
candidate for
switching to an AI
first check E2 and
FSH levels
• Measurements
should be made at
baseline and then
serially (eg, every
3-6 months) during
treatment
Women of uncertain menopausal status who may be or may become eligible for an
adjuvant AI
Cessation of menses on tamoxifen
TREATMENT-NAÏVE: NATURAL MENOPAUSAL
TRANSITION
TREATMENT-INDUCED
AMENORRHOEA
CHEMOTHERAPY- INDUCED
WHILE ON
TAMOXIFEN
AGE < 40: AI ALONE IS
CONTRAINDICATED
AGE > 40
Start with tamoxifen
Monitor E2 and FSH every 3-6 months
Consider an AI as soon as menopausal status is confirmed
If E2 and FSH levels are post-menopausal by reliable & valid measure start AI
Monitor hormones at 3, 6 months and q6 during treatment
![Page 26: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/26.jpg)
Issues for ‘perimenopausal’ women started
on an aromatase inhibitor
• Contraception
• Hot flashes
• Sexual dysfunction and dyspareunia
• Bone Heath
![Page 27: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/27.jpg)
Serum estradiol levels in women receiving concurrent aromatase inhibitors and Vagifem.
Kendall A et al. Ann Oncol 2006;17:584-587
Avoid use of vaginal oestrogen preparations in women on aromatase inhibitors
![Page 28: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/28.jpg)
Bone health
• A baseline measurement of bone mineral density (BMD)
is recommended to guide future management.
• Advice on exercise, cessation of smoking and
moderation of alcohol should be provided.
• Adequate calcium (1g/day) and vitamin D (400-800 i.u.)
is advised in all postmenopausal women.
• Women with BMD T score of <-2 or <-1 and annual bone
loss > 4%/year should be considered for bisphosphonate
treatment
DM Reid et al. Cancer Treatment Reviews 34, Suppl 1, S3-S18, 2008.
P Hadji et al. Annals of Oncology 2008; 19: 1407-1416.
![Page 29: Treatment of Perimenopausal Women with Breast cancer · Definition of menopause1 Menopause Bilateral prior oophorectomy Age >60 years Age 12 months](https://reader034.fdocuments.in/reader034/viewer/2022042108/5e88e97b9ec0754cb610bbea/html5/thumbnails/29.jpg)
Summary
• When menopausal status is uncertain, starting endocrine therapy with tamoxifen rather than an AI provides effective treatment while allowing a period during which the patient’s menopausal status may become clearer. If in doubt wait!
• However, given the benefit certain women may gain from receiving an AI rather than continuing on tamoxifen, it is important regularly to monitor the hormonal status of perimenopausal patients so that treatment can be switched when appropriate.